N
IMVT icon

Natixis’s Immunovant IMVT Stock Holding History

Natixis’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,900
Closed -$712K – 1117
2023
Q4 		$712K Buy
+16,900
New +$622K 0.01% 574

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Natixis's IMVT Position: Q1 2024 in Review

Natixis sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 16,900 shares — an estimated $712K sold.

Natixis first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $712K in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Natixis reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 16,900 Immunovant shares in Q1 2024, an estimated $712K.
  • Natixis first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
  • Natixis's Immunovant position peaked at $712K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.